ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development In Osteoarthritis With The Potential For Disease-Modifying Activity

Podiatry Arena ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development In Osteoarthritis With The Potential For Disease-Modifying Activity

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development In Osteoarthritis With The Potential For Disease-Modifying Activity

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

9th January 2009, 09:10 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 3,061

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 5 Times in 5 Posts

ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development In Osteoarthritis With The Potential For Disease-Modifying Activity

Podiatry Arena members do not see these ads

ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of the Phase I/IIa clinical development of its anti-TNF alpha antibody fragment ESBA105 in osteoarthritis (OA). This double-blind, randomized, placebo-controlled Phase I/IIa clinical study is designed to investigate the safety, tolerability and efficacy on pain with ESBA105 applied locally via intra-articular administration to patients with severely painful OA of the knee.

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
CrystalGenomics Announces Positive Phase IIa Results For Osteoarthritis Study Of CG100649	RSSFeedBot	Latest Rheumatology News	0	23rd December 2008 04:30 AM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 06:12 PM.

User Name		Remember Me?
Password